Pharmacogenetic clinical randomized phase II trial to evaluate the efficacy and safety of FOLFIRI with high dose of irinotecan (FOLFIRI-HD) in metastatic colorectal cancer patients according to UGT1A 1 genotype

Subjects

Subjects :

0301 basic medicine
Oncology
medicine.medical_specialty
Colorectal cancer
business.industry
Phases of clinical research
Hematology
medicine.disease
Irinotecan
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
Genotype
medicine
FOLFIRI
business
Pharmacogenetics
medicine.drug

Details

ISSN :

09237534

Volume :

28

Database :

OpenAIRE

Journal :

Annals of Oncology

Accession number :

edsair.doi...........d28ec8f1f0f4de7c53ce38554ecf2df6

Full Text :

https://doi.org/10.1093/annonc/mdx263.031